Clinical Trials Browser

Interventional × Has results × selinexor × Clear all

NCT04856189 2026-01-29

Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma

Phase 1/2 Terminated

4 enrolled 8 charts

Carcinoma, Transitional Cell

NCT04216329 2026-01-23

Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma

Phase 1 Active not recruiting

11 enrolled 19 charts

Glioblastoma, Gliosarcoma

NCT02303392 2025-06-10

Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma

Phase 1 Completed

34 enrolled 14 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT03992339 2025-02-07

SEARCH

Phase 2 Completed

60 enrolled 9 charts

Lymphoma, Large B-Cell, Diffuse

NCT02323880 2025-01-14

Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas

Phase 1 Completed

59 enrolled 20 charts

Astrocytoma, Brain Neoplasms, Glioma, Lymphoma, Central Nervous System Neoplasms

NCT04421378 2024-12-16

A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma

Phase 1/2 Terminated

74 enrolled 23 charts

Glioblastoma

NCT04768881 2024-08-23

Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma

Phase 2 Terminated

15 enrolled 15 charts

Melanoma

NCT03110562 2024-08-21

BOSTON

Phase 3 Completed

402 enrolled 22 charts 1 FDA

Multiple Myeloma, Recurrence

NCT03095612 2024-06-13

Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)

Phase 1/2 Terminated

41 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT01896505 2024-01-08

A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma

Phase 1 Completed

54 enrolled 28 charts

Bone Neoplasms, Sarcoma

NCT02178436 2023-11-07

Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer

Phase 1/2 Completed

15 enrolled 13 charts

Gastrointestinal

Pancreatic Neoplasms

NCT04854434 2023-11-03

A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations

Phase 2 Terminated

13 enrolled 14 charts

Gastrointestinal

Colorectal Neoplasms

NCT04843579 2023-10-25

ClaSPd

Phase 2 Terminated

4 enrolled 9 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03944057 2023-06-15

MARCH

Phase 2 Completed

82 enrolled 9 charts

Multiple Myeloma, Recurrence

NCT03193437 2023-02-16

SELECT

Phase 2 Terminated

8 enrolled 11 charts

Thymoma

NCT01607892 2023-01-26

Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer

Phase 1 Completed

286 enrolled 26 charts

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01607905 2023-01-26

Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer

Phase 1 Completed

192 enrolled 29 charts

CNSDermatologicGastrointestinal

Adenocarcinoma, Carcinoma, Squamous Cell, Glioblastoma, Melanoma, Colorectal Neoplasms

NCT01986348 2023-01-26

KING

Phase 2 Terminated

76 enrolled 16 charts

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma

NCT02025985 2023-01-26

SIGN

Phase 2 Completed

116 enrolled 21 charts

Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT02088541 2023-01-26

SOPRA

Phase 2 Completed

317 enrolled 25 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02138786 2023-01-26

SIRRT

Phase 2 Terminated

27 enrolled 17 charts

Richter's Transformation

NCT02146833 2023-01-26

SHIP

Phase 2 Terminated

20 enrolled 13 charts

Prostatic Neoplasms

NCT02213133 2023-01-26

STARRS

Phase 2 Terminated

45 enrolled 12 charts

Carcinoma, Carcinoma, Squamous Cell

NCT02314247 2023-01-26

Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma

Phase 2 Terminated

16 enrolled 16 charts

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT02336815 2023-01-26

STORM

Phase 2 Completed

202 enrolled 30 charts 1 FDA

Multiple Myeloma

NCT02606461 2023-01-23

SEAL

Phase 2/3 Completed

342 enrolled 36 charts

Liposarcoma

NCT02186834 2023-01-04

Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma

Phase 1/2 Completed

28 enrolled 10 charts

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT02780609 2022-11-04

Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Phase 1/2 Completed

22 enrolled 16 charts

Multiple Myeloma

NCT02384850 2022-04-08

SENTINEL

Phase 1 Terminated

10 enrolled 13 charts

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT02249091 2021-08-25

A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Phase 2 Completed

42 enrolled 16 charts

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT02402764 2020-09-11

Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC)

Phase 2 Completed

10 enrolled 7 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03071276 2020-05-22

Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia

Phase 2 Terminated

37 enrolled 11 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02530476 2020-03-31

Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia

Phase 1/2 Completed

17 enrolled 14 charts

Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT02416908 2020-03-13

Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia

Phase 1/2 Completed

40 enrolled 16 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02215161 2018-06-26

Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer

Phase 2 Terminated

14 enrolled 12 charts

Castration Levels of Testosterone

NCT02351505 2016-05-16

Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer

Phase 2 Terminated

1 enrolled 6 charts

Small Cell Lung Carcinoma